Wonbiogen Co., Ltd. (KOSDAQ:307280)
6,070.00
-100.00 (-1.62%)
At close: Sep 4, 2026
Wonbiogen Revenue
Wonbiogen had revenue of 9.93B KRW in the quarter ending June 30, 2026, with 18.26% growth. This brings the company's revenue in the last twelve months to 37.80B, up 18.04% year-over-year. In the year 2025, Wonbiogen had annual revenue of 35.24B with 15.78% growth.
Revenue (ttm)
37.80B
Revenue Growth
+18.04%
P/S Ratio
1.09
Revenue / Employee
n/a
Employees
n/a
Market Cap
41.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.24B | 4.80B | 15.78% |
| Dec 31, 2024 | 30.44B | 824.93M | 2.79% |
| Dec 31, 2023 | 29.61B | 2.87B | 10.72% |
| Dec 31, 2022 | 26.75B | 9.03B | 50.94% |
| Dec 31, 2021 | 17.72B | 5.70B | 47.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KM Corporation | 144.10B |
| JW Shinyak | 81.04B |
| Sewoon Medical | 66.53B |
| CG MedTech | 51.20B |
| OSTEONIC | 50.97B |
| DuChemBIO | 41.51B |
| SCL Science | 30.50B |
| Plasmapp | 12.02B |